Filtered By:
Specialty: Cardiology
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 932 results found since Jan 2013.

When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy.
Abstract OPINION STATEMENT: For secondary stroke prevention, long-term dual antiplatelet therapy is not recommended due to increased bleeding risks. There is no specific evidence for using dual antiplatelet therapy for cervical artery dissection or for adding a second antiplatelet agent after a stroke while taking aspirin monotherapy. For patients with atrial fibrillation and stroke/TIA unable to tolerate warfarin, aspirin monotherapy is reasonable. Dual antiplatelet therapy carries a similar risk of major bleeding as warfarin that offsets reductions in stroke risk. Dual antiplatelet therapy is recommended for end...
Source: Atherosclerosis - February 27, 2016 Category: Cardiology Authors: Yuan K, Kim AS Tags: Curr Treat Options Cardiovasc Med Source Type: research

Hsp70 protects from stroke in atrial fibrillation patients by preventing thrombosis without increased bleeding risk
Conclusions Hsp70 induction is a novel approach to delay thrombus formation with minimal bleeding risk, and is especially promising for treating AF patients and in other situations where there is also a major bleeding hazard.
Source: Cardiovascular Research - May 18, 2016 Category: Cardiology Authors: Allende, M., Molina, E., Guruceaga, E., Tamayo, I., Gonzalez-Porras, J. R., Gonzalez-Lopez, T. J., Toledo, E., Rabal, O., Ugarte, A., Roldan, V., Rivera, J., Oyarzabal, J., Montes, R., Hermida, J. Tags: Integrative physiology and pathophysiology Source Type: research

Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
We report the case of an elderly patient with permanent AF and coronary heart disease, who had already suffered an ischemic stroke while on warfarin treatment, and was consequently switched to treatment with an association of Rivaroxaban and Aspirin. Her CHA2DS2-VASc score was 9. The patient developed a severe recurrent disabling ischemic stroke. This case goes to show that the novel direct anticoagulants may fail to prevent recurrent stroke in patients at particularly high risk, even when associated with antiplatelet drugs. PMID: 27228488 [PubMed - as supplied by publisher]
Source: Minerva Cardioangiologica - May 27, 2016 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

Stroke Caused by Atherosclerosis of the Major Intracranial Arteries.
Abstract Our goal in this review is to discuss the pathophysiology, diagnosis, and treatment of stroke caused by atherosclerosis of the major intracranial arteries. References for the review were identified by searching PubMed for related studies published from 1955 to June 2016 using search terms intracranial stenosis and intracranial atherosclerosis. Reference sections of published randomized clinical trials and previously published reviews were searched for additional references. Intracranial atherosclerotic disease is a highly prevalent cause of stroke that is associated with a high risk of recurrent stroke. I...
Source: Circulation Research - February 2, 2017 Category: Cardiology Authors: Banerjee C, Chimowitz MI Tags: Circ Res Source Type: research

Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation?
CONCLUSIONS: High vWF plasma concentrations may discriminate patients with NVAF at greater risk of stroke or all-cause death. PMID: 29685722 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - April 20, 2018 Category: Cardiology Authors: Ancedy Y, Berthelot E, Lang S, Ederhy S, Boyer-Chatenet L, Di Angelantonio E, Soulat-Dufour L, Etienney A, Adavane-Scheublé S, Boccara F, Cohen A Tags: Arch Cardiovasc Dis Source Type: research

Oral Anticoagulants vs. Aspirin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation: The Verdict is in
This article summarizes a recently published individual patient meta-analysis of all published RCTs comparing OAC and ASA in AF. In total, 4052 patients randomized to OAC or ASA were similar regarding important prognostic factors. Patients receiving OAC had a significantly lower risk of any stroke (hazard ratio [HR] 0.54 [95% CI 0.43 –0.71]), ischemic stroke (HR 0.48 [0.37–0.63]), or cardiovascular events (HR 0.71 [0.59–0.85]). Patients receiving OAC were more likely to experience major bleeding (HR 1.71 [1.21–2.41]). The benefit of OAC was most prominent in patients at a high risk of stroke and other cardiovascula...
Source: Cardiac Electrophysiology Review - December 1, 2003 Category: Cardiology Source Type: research

Temporary oral anticoagulation after MitraClip - a strategy to lower the incidence of post-procedural stroke?
CONCLUSIONS: Temporary oral anticoagulation might be a strategy to reduce the incidence of stroke within the first 30 days after the MitraClip procedure. Bleeding events were not significantly altered due to temporary oral anticoagulation. PMID: 30650019 [PubMed - as supplied by publisher]
Source: Acta Cardiologica - January 18, 2019 Category: Cardiology Tags: Acta Cardiol Source Type: research

Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
CONCLUSIONS: Homocysteine could be a potential biomarker to discriminate the effects of dual and single antiplatelet therapy in female patients with minor ischemic stroke or high-risk transient ischemic attack. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589. PMID: 31941381 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - January 15, 2020 Category: Cardiology Authors: Li J, Wang Y, Li H, Zuo Z, Lin J, Wang A, Zhao X, Liu L, Wang Y, CHANCE Investigators* Tags: Arterioscler Thromb Vasc Biol Source Type: research

A Clinical Update on Antiplatelet Therapy in Secondary Prevention of Ischemic Stroke
AbstractPurpose of ReviewAntiplatelet therapy remains the standard of care in secondary stroke prevention for non-cardioembolic ischemic stroke and transient ischemic attack. We aim to examine the use of antiplatelet agents in secondary prevention through highlighting relevant clinical trials and meta-analyses as well as providing commentary regarding our practice.Recent FindingsIn the POINT and CHANCE trials, dual antiplatelet therapy reduced recurrent stroke compared to aspirin monotherapy. Sub-analyses of these trials suggest that genetic polymorphisms could play a role in diminishing the effectiveness of clopidogrel. S...
Source: Current Cardiology Reports - August 19, 2021 Category: Cardiology Source Type: research

Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial.
CONCLUSIONS: The "local" strategy of LAA closure is noninferior to "systemic" anticoagulation with Warfarin. PROTECT AF has, for the first time, implicated the LAA in the pathogenesis of stroke in AF. CLINICAL TRIAL REGISTRATION INFORMATION: Clinicaltrials.gov; Unique Identifier: NCT00129545. PMID: 23325525 [PubMed - as supplied by publisher]
Source: Circulation - January 16, 2013 Category: Cardiology Authors: Reddy VY, Doshi SK, Siever H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D Tags: Circulation Source Type: research

Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study
Atrial fibrillation is the most common cardiac arrhythmia, and age is a well-established independent risk factor for stroke in these patients. Whereas high-risk patients clearly benefit from anticoagulation to prevent stroke, less is known about how to treat low-risk patients. Despite the recent guidelines and studies demonstrating no benefit and excess bleeding risk with aspirin, many low-risk patients still receive this medication. Our objective was to determine the stroke rate in young patients with atrial fibrillation, a group of previously unstudied and predominantly low-risk patients. We hypothesized that the event r...
Source: Journal of Cardiovascular Medicine - March 1, 2014 Category: Cardiology Tags: Original articles: Atrial fibrillation Source Type: research

ABI and stroke: Action at a distance and a call to action
Stroke is a catastrophic clinical event and is justifiably feared by both patients and physicians alike. Given the aging demographic of western populations, the morbid consequences of stroke are also a growing burden on healthcare resources . For example, projections show that by 2030 an additional 3.4 million US adults will have suffered a stroke, a 20.5% increase in prevalence from 2012 . The majority of strokes are ischemic and a consequence of either thromboembolism or atherosclerosis or both. Fortunately, effective primary prevention therapies exist, including aspirin and statins , which can reduce the risk of ischemi...
Source: Atherosclerosis - April 10, 2014 Category: Cardiology Authors: John W. McEvoy, Khurram Nasir Tags: Invited Commentaries Source Type: research

Abstract 262: Aspirin vs. Warfarin Therapy Outcomes for Non-Valvular Atrial Fibrillation Patients with Moderate Stroke Risk Session Title: Poster Session II
Conclusion: ASA therapy was associated with a higher rate of stroke/SE but with a lower rate of bleed compared to TTR ≥55% warfarin in NVAF patients with CHADS2=1. These results suggest that treatment decisions should be carefully made based on the risk and benefit assessment in patients whose CHADS2=1.
Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: An, J., Jazdzewski, K. P., Le, P. T., Rashid, N., Lang, D. T., Niu, F., Meissner, B., Mendes, R., Dills, D., Bruno, A. Tags: Session Title: Poster Session II Source Type: research

Antiplatelet Strategies for Secondary Prevention of Stroke and TIA
Abstract Stroke is a major public health issue, and stroke recurrence accounts for a quarter of all events. Antiplatelet therapy has been extensively studied for secondary stroke prevention and is established as effective in this high-risk population. Several agents have been evaluated in this setting, both in isolation and combination. The most widely used antiplatelet medications are aspirin, clopidogrel, and aspirin plus extended-release dipyridamole. However, new agents and combinations continue to be evaluated. A detailed review of the evidence supporting various antiplatelet regimens for secondary stroke pr...
Source: Current Atherosclerosis Reports - September 10, 2014 Category: Cardiology Source Type: research

Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk
Conclusion Left atrial appendage closure in patients with non-valvular atrial fibrillation and high risk for stroke and bleeding events effectively prevented stroke and reduced cerebral ischemic events compared to expected stroke rate according to CHA2DS2-VASc Score. Dual antiplatelet therapy for 3 months reduced the rate of bleeding events compared to 6 months therapy with no increase of thrombotic events.
Source: Clinical Research in Cardiology - August 29, 2015 Category: Cardiology Source Type: research